KT

Kintara Therapeutics IncNASDAQ KTRA Stock Report

Last reporting period 31 Dec, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

0.009

Micro

Exchange

XNAS - Nasdaq

KTRA Stock Analysis

KT

Uncovered

Kintara Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.009

Dividend yield

Shares outstanding

1.675 B

Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. The company is headquartered in San Diego, California and currently employs 3 full-time employees. The company went IPO on 2016-07-12. The firm is developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to available therapies, with particular focus on orphan cancer indications. The Company’s two lead candidates include VAL-083 and REM-001. Its VAL-083 is a novel, validated, deoxyribonucleic acid (DNA) targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG) The Company’s REM-001, a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC); basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients.

View Section: Eyestock Rating